[Optic atrophy, recurrent deterioration of vision and Raynaud's phenomenon].
Papageorgiou
E
E
Abt. für Pathophysiologie des Sehens und Neuroophthalmologie, Universitätsaugenklinik Tübingen, Schleichstrasse 12-16, 72076, Tübingen, Deutschland. Eleni.Papageorgiou@med.uni-tuebingen.de
Schiefer
U
U
Dörnberger
V
V
Leo-Kottler
B
B
D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D003095:Collagen Diseases / Q000175:diagnosis* / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D009896:Optic Atrophy / Q000175:diagnosis* / Q000188:drug therapy; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage; D011928:Raynaud Disease / Q000175:diagnosis* / Q000188:drug therapy; D018860:Sneddon Syndrome / Q000175:diagnosis / Q000188:drug therapy; D014786:Vision Disorders / Q000175:diagnosis* / Q000188:drug therapy; D014794:Visual Fields
D000974:Antibodies, Antinuclear; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone